IO Biotech (IOBT) Competitors

IO Biotech (NASDAQ:IOBT) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Which has preferable earnings and valuation, IOBT or RNAC?

IO Biotech has higher earnings, but lower revenue than Cartesian Therapeutics. IO Biotech is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IO Biotech	N/A	N/A	-$86.08M	-$1.37	-0.75
Cartesian Therapeutics	$34.17M	7.77	-$219.71M	-$52.83	-0.19

Does the media prefer IOBT or RNAC?

In the previous week, IO Biotech and IO Biotech both had 8 articles in the media. IO Biotech's average media sentiment score of 0.82 beat Cartesian Therapeutics' score of 0.33 indicating that IO Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IO Biotech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts rate IOBT or RNAC?

IO Biotech presently has a consensus target price of $9.33, indicating a potential upside of 806.15%. Cartesian Therapeutics has a consensus target price of $42.50, indicating a potential upside of 315.44%. Given IO Biotech's stronger consensus rating and higher possible upside, analysts plainly believe IO Biotech is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Cartesian Therapeutics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Do insiders & institutionals have more ownership in IOBT or RNAC?

54.8% of IO Biotech shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 4.8% of IO Biotech shares are owned by company insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is IOBT or RNAC more profitable?

IO Biotech has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat IO Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IO Biotech	N/A	-86.56%	-75.24%
Cartesian Therapeutics	-510.72%	N/A	-6.03%

Does the MarketBeat Community prefer IOBT or RNAC?

Cartesian Therapeutics received 13 more outperform votes than IO Biotech when rated by MarketBeat users. Likewise, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 92.86% of users gave IO Biotech an outperform vote.

Company	Underperform	Outperform
IO Biotech	Outperform Votes 26 92.86%	Underperform Votes 2 7.14%
Cartesian Therapeutics	Outperform Votes 39 95.12%	Underperform Votes 2 4.88%

Which has more risk & volatility, IOBT or RNAC?

IO Biotech has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Summary

Cartesian Therapeutics beats IO Biotech on 10 of the 17 factors compared between the two stocks.